PH12018501978A1 - Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibody - Google Patents
Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibodyInfo
- Publication number
- PH12018501978A1 PH12018501978A1 PH12018501978A PH12018501978A PH12018501978A1 PH 12018501978 A1 PH12018501978 A1 PH 12018501978A1 PH 12018501978 A PH12018501978 A PH 12018501978A PH 12018501978 A PH12018501978 A PH 12018501978A PH 12018501978 A1 PH12018501978 A1 PH 12018501978A1
- Authority
- PH
- Philippines
- Prior art keywords
- ngf antibody
- pharmaceutical composition
- fab fragment
- human ngf
- pegylated fab
- Prior art date
Links
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000007951 isotonicity adjuster Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016061353 | 2016-03-25 | ||
| PCT/JP2017/011910 WO2017164349A1 (ja) | 2016-03-25 | 2017-03-24 | ＰＥＧ化抗ヒトＮＧＦ抗体Ｆａｂ'フラグメント含有医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12018501978A1 true PH12018501978A1 (en) | 2019-06-17 |
Family
ID=59900467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12018501978A PH12018501978A1 (en) | 2016-03-25 | 2018-09-13 | Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibody |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200299371A1 (enExample) |
| EP (1) | EP3434283A4 (enExample) |
| JP (2) | JPWO2017164349A1 (enExample) |
| KR (1) | KR20180123559A (enExample) |
| CN (1) | CN108883177A (enExample) |
| CA (1) | CA3018473A1 (enExample) |
| MX (1) | MX2018011675A (enExample) |
| PH (1) | PH12018501978A1 (enExample) |
| RU (1) | RU2018137495A (enExample) |
| SG (1) | SG11201808119UA (enExample) |
| TW (1) | TW201738269A (enExample) |
| WO (1) | WO2017164349A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201718888D0 (en) * | 2017-11-15 | 2017-12-27 | Ucb Biopharma Sprl | Method |
| CN112839683B (zh) * | 2018-10-10 | 2023-11-14 | 安斯泰来制药株式会社 | 含有标记部-抗人抗体Fab片段复合物的药物组合物 |
| CN121079108A (zh) * | 2023-05-12 | 2025-12-05 | 五稜化药株式会社 | 冻结干燥制剂、冻结干燥溶液和这些的制造方法、以及液剂 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| WO2005063291A1 (ja) * | 2003-12-25 | 2005-07-14 | Kirin Beer Kabushiki Kaisha | 抗体を含有する安定な水性医薬製剤 |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| JP5642683B2 (ja) | 2008-09-19 | 2014-12-17 | ファイザー・インク | 安定な液体抗体配合物 |
| CA2790699A1 (en) * | 2010-03-17 | 2011-09-22 | Abbott Research B.V. | Anti-nerve growth factor (ngf) antibody compositions |
| WO2013022083A1 (ja) * | 2011-08-11 | 2013-02-14 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
| JP6135161B2 (ja) * | 2013-02-08 | 2017-05-31 | アステラス製薬株式会社 | 新規抗ヒトｎｇｆ抗体 |
-
2017
- 2017-03-24 TW TW106109999A patent/TW201738269A/zh unknown
- 2017-03-24 SG SG11201808119UA patent/SG11201808119UA/en unknown
- 2017-03-24 JP JP2018507426A patent/JPWO2017164349A1/ja active Pending
- 2017-03-24 CA CA3018473A patent/CA3018473A1/en not_active Abandoned
- 2017-03-24 KR KR1020187030401A patent/KR20180123559A/ko not_active Ceased
- 2017-03-24 MX MX2018011675A patent/MX2018011675A/es unknown
- 2017-03-24 US US16/087,908 patent/US20200299371A1/en not_active Abandoned
- 2017-03-24 WO PCT/JP2017/011910 patent/WO2017164349A1/ja not_active Ceased
- 2017-03-24 RU RU2018137495A patent/RU2018137495A/ru unknown
- 2017-03-24 CN CN201780019929.0A patent/CN108883177A/zh active Pending
- 2017-03-24 EP EP17770389.9A patent/EP3434283A4/en not_active Ceased
-
2018
- 2018-09-13 PH PH12018501978A patent/PH12018501978A1/en unknown
-
2021
- 2021-11-10 JP JP2021182945A patent/JP7215555B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180123559A (ko) | 2018-11-16 |
| RU2018137495A3 (enExample) | 2020-05-25 |
| MX2018011675A (es) | 2019-01-10 |
| RU2018137495A (ru) | 2020-04-27 |
| US20200299371A1 (en) | 2020-09-24 |
| CA3018473A1 (en) | 2017-09-28 |
| TW201738269A (zh) | 2017-11-01 |
| EP3434283A4 (en) | 2019-11-13 |
| JP7215555B2 (ja) | 2023-01-31 |
| WO2017164349A1 (ja) | 2017-09-28 |
| JP2022023223A (ja) | 2022-02-07 |
| JPWO2017164349A1 (ja) | 2019-02-07 |
| SG11201808119UA (en) | 2018-10-30 |
| EP3434283A1 (en) | 2019-01-30 |
| CN108883177A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1126062T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
| MY185802A (en) | Antibody formulation | |
| SA519401646B1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| HRP20211343T1 (hr) | Protutijela protiv dkk-1 | |
| UA118441C2 (uk) | Антитіло, що розпізнає альфа-синуклеїн | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| UA113728C2 (xx) | Фармацевтична композиція, яка містить антитіло до pcsk9 людини | |
| CY1116762T1 (el) | Πολυπεπτιδια, μεταβλητες περιοχες αντισωματος και ανταγωνιστες | |
| AR082916A1 (es) | Moleculas de union a 4-1bb | |
| WO2014139476A8 (zh) | Rsv融合蛋白的表位以及识别其的抗体 | |
| EP3807318A4 (en) | MULTISPECIFIC ANTIBODY CONSTRUCTS | |
| CO6270369A2 (es) | Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas | |
| PH12018501978A1 (en) | Pharmaceutical composition comprising pegylated fab fragment of anti-human ngf antibody | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| ECSP17044282A (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| WO2015051264A8 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| CR20130021A (es) | El nuevo estable polietileno glicol conjugado en interferon alfa, representado por un isómero posicional | |
| EP3927729A4 (en) | Therapeutic antibody formulation | |
| EP3770262A4 (en) | ANTIBODY FRAGMENT DEGRADING AND REMOVING ABNORMOUS TDP-43 | |
| CO2020006120A2 (es) | Formulación | |
| EP3432925A4 (en) | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY | |
| EP3963047A4 (en) | ALPHA SYNUCLEIN ASSAYS | |
| MX2018005226A (es) | Formulaciones de anticuerpo anti-factor d. | |
| HRP20240951T1 (hr) | LjUDSKO PROTUTIJELO PROTIV VRSTA ADAMTS TIPA AGREKANAZE ZA TERAPEUTSKA SREDSTVA KOD BOLESTI VEZANIH UZ AGREKANAZE | |
| MA52238A (fr) | Conjugués de médicament d'agents de liaison monoclonaux cmet, et utilisations associées |